Clinical observation of body-gamma knife combined with recombinant human endostatin injection (Endostar) as the therapy in the elderly patients with advanced non-small cell lung cancers

Abstract

Objective To explore the efficacy and safety of human recombinant vascular endothelial inhibition (en) combined with gamma knife in the treatment of elderly advanced non-small cell lung cancer patents. Methods Totally 38 cases of senile non-small cell lung cancer patients were divided into two groups: A group was treatment group with 17 cases of recombinant human endostatin combined with gamma knife, group B was control group with 21 cases of patients receiving body gamma knife alone. Recombinant human endostatin was given intravenously 15 mg per day in 500 ml of saline for 3~4 hours for 14 days a cycle, and the total dose of body gamma knife therapy was 36~48 Gy/10~12f. Results The response rate (RR) of groups A and B were 58.82% and 57.14% without statistical difference. One-year survival rate of groups A and B were 47.06% and 38.09%, respectively; and there was no statistical significance. The main side-effects of both groups were bone marrow suppression and gastrointestinal reactions, but no statistical difference was observed. Two groups of patients' quality of life were improved without statistical difference (P>0.05). Conclusions Body-gamma knife therapy combined with recombinant human endostatin in elderly advanced non-small cell lung cancer patients has better efficacy such as CR rate and long-term survival, and similar side-effects. Key words: Radiosurgery; Endostatins/TU; Carcinoma, non-small-cell lung/TH